209 related articles for article (PubMed ID: 21251891)
1. Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis.
Stanich PP; Björnsson E; Gossard AA; Enders F; Jorgensen R; Lindor KD
Dig Liver Dis; 2011 Apr; 43(4):309-13. PubMed ID: 21251891
[TBL] [Abstract][Full Text] [Related]
2. Alkaline phosphatase normalization is a biomarker of improved survival in primary sclerosing cholangitis.
Hilscher M; Enders FB; Carey EJ; Lindor KD; Tabibian JH
Ann Hepatol; 2016; 15(2):246-53. PubMed ID: 26845602
[TBL] [Abstract][Full Text] [Related]
3. Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis.
Lindström L; Hultcrantz R; Boberg KM; Friis-Liby I; Bergquist A
Clin Gastroenterol Hepatol; 2013 Jul; 11(7):841-6. PubMed ID: 23353641
[TBL] [Abstract][Full Text] [Related]
4. Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis.
Al Mamari S; Djordjevic J; Halliday JS; Chapman RW
J Hepatol; 2013 Feb; 58(2):329-34. PubMed ID: 23085647
[TBL] [Abstract][Full Text] [Related]
5. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.
Lindor KD; Kowdley KV; Luketic VA; Harrison ME; McCashland T; Befeler AS; Harnois D; Jorgensen R; Petz J; Keach J; Mooney J; Sargeant C; Braaten J; Bernard T; King D; Miceli E; Schmoll J; Hoskin T; Thapa P; Enders F
Hepatology; 2009 Sep; 50(3):808-14. PubMed ID: 19585548
[TBL] [Abstract][Full Text] [Related]
6. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial.
Beuers U; Spengler U; Kruis W; Aydemir U; Wiebecke B; Heldwein W; Weinzierl M; Pape GR; Sauerbruch T; Paumgartner G
Hepatology; 1992 Sep; 16(3):707-14. PubMed ID: 1505913
[TBL] [Abstract][Full Text] [Related]
7. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.
Fickert P; Hirschfield GM; Denk G; Marschall HU; Altorjay I; Färkkilä M; Schramm C; Spengler U; Chapman R; Bergquist A; Schrumpf E; Nevens F; Trivedi P; Reiter FP; Tornai I; Halilbasic E; Greinwald R; Pröls M; Manns MP; Trauner M;
J Hepatol; 2017 Sep; 67(3):549-558. PubMed ID: 28529147
[TBL] [Abstract][Full Text] [Related]
8. Alkaline phosphatase at diagnosis of primary sclerosing cholangitis and 1 year later: evaluation of prognostic value.
de Vries EM; Wang J; Leeflang MM; Boonstra K; Weersma RK; Beuers UH; Geskus RB; Ponsioen CY
Liver Int; 2016 Dec; 36(12):1867-1875. PubMed ID: 26945698
[TBL] [Abstract][Full Text] [Related]
9. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study.
Olsson R; Boberg KM; de Muckadell OS; Lindgren S; Hultcrantz R; Folvik G; Bell H; Gangsøy-Kristiansen M; Matre J; Rydning A; Wikman O; Danielsson A; Sandberg-Gertzén H; Ung KA; Eriksson A; Lööf L; Prytz H; Marschall HU; Broomé U
Gastroenterology; 2005 Nov; 129(5):1464-72. PubMed ID: 16285948
[TBL] [Abstract][Full Text] [Related]
10. Short-term prognostic factors for primary sclerosing cholangitis.
Watanabe T; Hirano K; Tada M; Isayama H; Mizuno S; Arizumi T; Toda N; Sugawara Y; Kokudo N; Koike K
J Hepatobiliary Pancreat Sci; 2015 Jun; 22(6):486-90. PubMed ID: 25826613
[TBL] [Abstract][Full Text] [Related]
11. Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses.
van Hoogstraten HJ; Wolfhagen FH; van de Meeberg PC; Kuiper H; Nix GA; Becx MC; Hoek AC; van Houte DP; Rijk MC; Salemans JM; Scherpenisse J; Schrijver M; Smit AM; Spoelstra P; Stadhouders PH; Tan TG; Hop WC; ten Kate FJ; vanBerge-Henegouwen GP; Schalm SW; van Buuren HR
J Hepatol; 1998 Sep; 29(3):417-23. PubMed ID: 9764988
[TBL] [Abstract][Full Text] [Related]
12. Reduction in alkaline phosphatase is associated with longer survival in primary sclerosing cholangitis, independent of dominant stenosis.
Rupp C; Rössler A; Halibasic E; Sauer P; Weiss KH; Friedrich K; Wannhoff A; Stiehl A; Stremmel W; Trauner M; Gotthardt DN
Aliment Pharmacol Ther; 2014 Dec; 40(11-12):1292-301. PubMed ID: 25316001
[TBL] [Abstract][Full Text] [Related]
13. Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase.
Murillo Perez CF; Harms MH; Lindor KD; van Buuren HR; Hirschfield GM; Corpechot C; van der Meer AJ; Feld JJ; Gulamhusein A; Lammers WJ; Ponsioen CY; Carbone M; Mason AL; Mayo MJ; Invernizzi P; Battezzati PM; Floreani A; Lleo A; Nevens F; Kowdley KV; Bruns T; Dalekos GN; Gatselis NK; Thorburn D; Trivedi PJ; Verhelst X; Parés A; Janssen HLA; Hansen BE;
Am J Gastroenterol; 2020 Jul; 115(7):1066-1074. PubMed ID: 32618657
[TBL] [Abstract][Full Text] [Related]
14. Fenofibrate in primary sclerosing cholangitis; a randomized, double-blind, placebo-controlled trial.
Hatami B; Mosala M; Hassani AH; Ardakani MJE; Gholami S; Zali MR
Pharmacol Res Perspect; 2022 Aug; 10(4):e00984. PubMed ID: 35822553
[TBL] [Abstract][Full Text] [Related]
15. Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis: Predictors of Gamma Glutamyltransferase Normalization and Favorable Clinical Course.
Deneau M; Perito E; Ricciuto A; Gupta N; Kamath BM; Palle S; Vitola B; Smolka V; Ferrari F; Amir AZ; Miloh T; Papadopoulou A; Mohan P; Mack C; Kolho KL; Iorio R; El-Matary W; Venkat V; Chan A; Saubermann L; Valentino PL; Shah U; Miethke A; Lin H; Jensen MK
J Pediatr; 2019 Jun; 209():92-96.e1. PubMed ID: 30878206
[TBL] [Abstract][Full Text] [Related]
16. The resurgence of serum alkaline phosphatase as a surrogate biomarker for prognosis in primary sclerosing cholangitis.
Talwalkar JA; Chapman RW
Clin Gastroenterol Hepatol; 2013 Jul; 11(7):847-9. PubMed ID: 23591287
[No Abstract] [Full Text] [Related]
17. Ursodeoxycholic acid for primary sclerosing cholangitis.
Chazouillères O; Poupon R; Capron JP; Metman EH; Dhumeaux D; Amouretti M; Couzigou P; Labayle D; Trinchet JC
J Hepatol; 1990 Jul; 11(1):120-3. PubMed ID: 1975818
[TBL] [Abstract][Full Text] [Related]
18. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group.
Lindor KD
N Engl J Med; 1997 Mar; 336(10):691-5. PubMed ID: 9041099
[TBL] [Abstract][Full Text] [Related]
19. Characteristics and clinical course of primary sclerosing cholangitis in France: a prospective cohort study.
Garioud A; Seksik P; Chrétien Y; Corphechot C; Poupon R; Poupon RE; Chazouillères O
Eur J Gastroenterol Hepatol; 2010 Jul; 22(7):842-7. PubMed ID: 19779305
[TBL] [Abstract][Full Text] [Related]
20. Primary sclerosing cholangitis with normal serum alkaline phosphatase activity.
Balasubramaniam K; Wiesner RH; LaRusso NF
Gastroenterology; 1988 Nov; 95(5):1395-8. PubMed ID: 3169503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]